Semaglutide (Wegovy) explained

Overview

Semaglutide, sold for weight management as Wegovy, is a once-weekly GLP-1 receptor agonist. NICE TA875 recommends it within a specialist weight-management service, with a maximum of two years of treatment.

Why it's done and who it helps

• Doses escalate 0.25 mg, 0.5 mg, 1 mg, 1.7 mg to 2.4 mg weekly.
• NICE recommends stopping at two years under TA875.
• Treatment should be reviewed and stopped if less than 5% weight loss at six months.
• It also has recognised cardiovascular risk-reduction data in people with established disease.

The two-year cap

The two-year limit is a NICE commissioning rule based on the trial evidence available, not a safety cut-off invented locally. Your monitoring record tracks your start date and flags the cap in advance so a plan is made early.

Judging response at six months

If total weight loss is under 5% at 26 weeks and adherence has been good, continuing is usually not justified. We look at waist, blood pressure, HbA1c and proteinuria as well as the scale.

Coming off semaglutide

Appetite returns over several weeks after stopping and weight regain is common without a maintenance plan. We taper deliberately and put structured food, protein and training habits in place first.

Preparing for your appointment

Why is there a two-year limit for Wegovy but not Mounjaro?

The limits come from separate NICE technology appraisals with different evidence bases; TA875 specifies two years for semaglutide.

Can I switch from Wegovy to Mounjaro?

Often yes, at a consultation — the switch is not dose-for-dose and restarts a low escalation step.

When to contact your care team

Contact the clinic promptly if you have any of the following:

• Vomiting or diarrhoea lasting more than 24 hours, or you cannot keep fluids down
• Passing much less urine than usual, or new swelling of the legs or face
• Severe pain in the upper abdomen that spreads to your back, with or without vomiting
• A weight change of more than 2 kg in a week that is not explained by fluid
• A missed weekly weight, a missed dose, or any hospital admission

If you are seriously unwell, contact NHS 111 or your renal unit directly rather than waiting for your next review.

Your care at KidneyWeight Clinic

Every dose change, weekly weight and kidney blood test is recorded in your clinical monitoring record, reviewed by Professor Mohammed Mahdi Althaf at six-weekly intervals and formally reassessed at 26 weeks. Booking and your initial payment are handled by professoralthaf.co.uk, medication supply by Healist Pharmacy, and follow-up appointment payments by Carebit.

References

• NICE TA1026: tirzepatide for managing overweight and obesity
• NICE TA875: semaglutide for managing overweight and obesity
• NICE CG189: obesity identification, assessment and management
• NHS: weight-loss medicines

This article is general patient information reviewed by a consultant nephrologist. It is not individual medical advice; treatment decisions are made at a face-to-face consultation.